Cargando…
Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study
Multiple sclerosis patients treated with anti-CD20 therapy (aCD20-MS) are considered especially vulnerable to complications from SARS-CoV-2 infection due to severe B-cell depletion with limited viral antigen-specific immunoglobulin production. Therefore, multiple vaccine doses as part of the primary...
Autores principales: | Alfonso-Dunn, Roberto, Lin, Jerry, Lei, Joyce, Liu, Jiayuan, Roche, Morgan, De Oliveira, Antonia, Raisingani, Amol, Kumar, Anjali, Kirschner, Vanessa, Feuer, Grant, Malin, Michaela, Sadiq, Saud A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338057/ https://www.ncbi.nlm.nih.gov/pubmed/37449202 http://dx.doi.org/10.3389/fimmu.2023.1194671 |
Ejemplares similares
-
Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies
por: Alfonso-Dunn, Roberto, et al.
Publicado: (2022) -
Humoral response to neurofilaments and dipeptide repeats in ALS progression
por: Puentes, Fabiola, et al.
Publicado: (2021) -
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
por: Marty, Paige K., et al.
Publicado: (2022) -
Repeated B-cell depletion with rituximab in rheumatoid arthritis
por: Edwards, J, et al.
Publicado: (2003) -
Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy
por: Antolí, Arnau, et al.
Publicado: (2022)